Artizan announces corporate progress and financing

Artizan Biosciences has announced corporate and financial updates:

  • Artizan has completed its Series A funding, bringing the total raised to date to $12 million.
  • Paul Miller, PhD, has been appointed as Chief Scientific Officer.
  • The company has moved to a 3,700 square-foot germ-free and gnotobiotic-enabled laboratory in Science Park in New Haven.

“We have made excellent progress identifying bacteria in the gut that predispose people to disease, and in our understanding of what those bacteria do to cause disease. This research is informing our development of potential therapies that neutralize or eliminate the pathogen, with an initial focus on IBD,” said James Rosen, President and Chief Executive Officer of Artizan.

more